We conducted a meta-analysis to investigate the association of 2 single nucleotide polymorphisms in the cytochrome P450, family 1, subfamily 1A1 gene (CYP1A1), CYP1A1*2A and CYP1A1*2C, with the risk of developing different subtypes of leukemia in adults and children. A total of 26 studies published between 1999 and 2011 were identified by searching the PubMed, EMBASE, Medline, and Web of Science databases. The odds ratios for the CYP1A1 polymorphisms and leukemia risk were calculated. The cumulative evidence in genetic associations was graded by using the Venice criteria of the Human Genome Epidemiology Network (Atlanta, Georgia). The results showed that the cumulative evidence was moderate for the association of the CYP1A1*2A variant with leukemia in Caucasians and with childhood acute lymphoid leukemia in Caucasians. In addition, there was moderate evidence that children who carry both the CYP1A1*2A variant and the glutathione S-transferase M1 null genotype have an increased risk of acute lymphoid leukemia. For the CYP1A1*2C polymorphism, the cumulative evidence of an association with leukemia risk was moderate for adults and weak for children. Logistic regression analysis demonstrated an interaction between the CYP1A1*2C polymorphism and age. This meta-analysis showed that the CYP1A1*2A and CYP1A1*2C polymorphisms were associated with an increased risk of leukemia, and that the associations might vary by ethnicity, gene-gene interactions, age, and leukemia subtype.
xenobiotic metabolizing enzymes, including cytochrome P450 enzymes (5) . The carcinogens are subsequently detoxified by phase II enzymes, such as glutathione S-transferase M1 (GSTM1). Polymorphisms in the genes of xenobiotic metabolizing enzymes may alter the expression or activity of the enzymes and, in turn, the risk of exposure-related cancers. In addition, the relationship with cancer risk may be age dependent, because many xenobiotic metabolizing enzymes, such as cytochrome P450 1A1 (CYP1A1), have distinct developmental patterns (6) .
CYP1A1, a major cytochrome P450 enzyme, contains 2 important single nucleotide polymorphisms, CYP1A1*2A (rs4646903) and CYP1A1*2C (rs1048943). CYP1A1*2A is a substitution of T with C in the 3′ untranslated region (7), whereas CYP1A1*2C involves an A to G transition creating an isoleucine/valine substitution in exon 7 (8) . Numerous studies have been conducted to investigate the relationship between the CYP1A1 polymorphisms and leukemia risk; however, results among studies are different, and previous meta-analyses considered only 1 or 2 leukemia subtypes (9) (10) (11) . Here, we conducted a meta-analysis of all eligible studies including all leukemia subtypes in both adults and children to determine the associations of the CYP1A1 polymorphisms with leukemia risk. We also aimed to shed light on the molecular mechanisms for subtype-specific and agerelated differences in the etiology of leukemia.
MATERIALS AND METHODS

Literature search
Studies published before September 30, 2012, were identified by searching the PubMed, EMBASE, Medline, and Web of Science databases for a combination of the following terms: "CYP1A1" or "CYPIA1" or "cytochrome p4501A1" and "polymorphism" and "leukemia" or "hematologic neoplasm" or "leukaemia." References from the retrieved articles were also searched for additional studies. No language restrictions were applied.
The following were inclusion criteria: 1) cases were primary or de novo leukemia; 2) the study investigated associations between CYP1A1 polymorphisms and leukemia risk in the general population; 3) the study used cohort or casecontrol design; 4) for different publications reporting on the same sample, only the most complete information was included. Studies reporting cases of secondary (therapyrelated) leukemia and studies lacking genetic information were excluded. In addition, meeting abstracts were excluded because of lack of sufficient information.
We also searched the PubMed, EMBASE, Medline, and Web of Science databases for genome-wide association studies of leukemia with the following terms: "leukemia" or "hematologic neoplasm" or "leukaemia" and "genome wide association study." We also searched the catalog of published genome-wide association studies (12) for studies of leukemia. By using a similar approach, we searched for genome-wide association studies that presented information on the association of CYP1A1 polymorphisms with the risks of all cancers. The latest searches were undertaken on September 30, 2012.
Data collection
Two authors extracted the following data independently from each of the eligible articles: first author, publication year, period of case diagnosis, country of origin, subtype of leukemia, diagnosis criteria of leukemia, age (child or adult), ethnicity, type of cases (incident or prevalent), and number of genotyped cases and controls. Study authors were contacted when there was insufficient information to determine the relationship between genetic polymorphism and leukemia risk. Disagreement was resolved by discussion between authors.
Ethnicity was categorized as "Caucasian," "Asian," or "Hispanic" according to the ethnic groups reported in the studies. When a study did not state the included ethnic groups but stated the nationality of the participants, we considered Turkish, Italian, Russian, and French Canadian origin to be "Caucasian"; Chinese, Indian, Korean, and Thai origin to be "Asian"; and Mexican origin to be "Hispanic." When articles reported data for different ethnic groups, results for the groups in each article were considered as separate studies. If it was impossible to separate participant data according to ethnicity, the participants were considered to be a "mixed population."
Assessment of study quality Study quality was rated by using established criteria (13) with slight modifications. First, we assessed HardyWeinberg equilibrium among controls. Second, the study type was defined as either epidemiologic or nonepidemiologic. For classification as an epidemiologic study, the following 4 criteria had to be met for the entire study population: case status and control status were confirmed by histology or cytology; ages of cases and controls were known; cases and controls were recruited from the same base population; and no case series were included. Third, study size was classified as studies with fewer than 200 participants and studies with 200 or more participants. High-quality studies were considered to be epidemiologic studies with controls in HardyWeinberg equilibrium and large study size.
Statistical analysis
Pooled odds ratios and 95% confidence intervals were used to assess the strength of the associations between leukemia risk and the CYP1A1 polymorphisms. The statistical significance of the pooled odds ratios was evaluated by using the Z test. Between-study heterogeneity was evaluated by using the Cochrane Q test and the I 2 statistic. I 2 values of 25%-50% indicate moderate inconsistencies, whereas values larger than 50% represent large inconsistencies among studies (14) . We used the random-effects model (DerSimonian and Laird's method (15) ) to calculate the odds ratio when the P value of the Cochrane Q test was <0.10 or the I 2 value was >50%; otherwise, the fixed-effects model was applied.
If more than 10 studies were included in a pooled analysis, a meta-regression analysis (the restricted maximum likelihood estimate method) was used to delineate the major sources of between-study heterogeneity (16) . The log odds ratios from each study were the dependent variables, and publication year, period of case diagnosis, country of origin, subtype of leukemia, age, ethnicity, low allele frequency in controls, and Hardy-Weinberg equilibrium were independent variables.
To assess deviation from Hardy-Weinberg equilibrium, we performed the appropriate goodness-of-fit χ 2 test. When there were more than 10 studies in an analysis, publication bias was evaluated by visualizing funnel plots and by Begg's rank correlation test (17) and Egger's linear regression test (18) . We conducted 2 sensitivity analyses. First, we examined to what extent results were affected by study quality in order to test the robustness of the conclusions. Second, we excluded 1 study at a time and analyzed the remaining ones to explore whether the results were influenced by a particular study. All statistical analyses were performed by using Stata, version 12, software (StataCorp LP, College Station, Texas) with 2-sided P values. Statistical significance was defined as P < 0.05.
Subgroup analyses
Studies were stratified by leukemia subtype, subject age, and ethnic group, and then by their combinations. The criteria for subgroup analyses required at least 4 high-quality studies. An additional subgroup analysis was performed by GSTM1 genotypes to evaluate whether CYP1A1*2A polymorphisms modified leukemia risks by interacting with GSTM1 polymorphisms. Effect modification by a subgroup was assessed by testing the interaction between genotypes and stratification variables by using logistic regression analyses (random-effects estimator) (19) .
Assessment of cumulative evidence
The Venice criteria proposed by the Human Genome Epidemiology Network were applied to assess the strength of the cumulative evidence on genetic associations. These criteria classify the credibility of cumulative epidemiologic evidence into grades of "A" (strong), "B" (moderate), or "C" (weak) on the basis of the amount of evidence, the extent of replication, and protection from bias (20) . The cumulative epidemiologic evidence of statistically significant associations was considered to be strong if all 3 grades were "A," moderate if all 3 grades were either "A" or "B," or weak if any grades were "C."
RESULTS
Eligibility and characteristics of the included studies
A diagram summarizing the process of study selection is shown in Figure 1 . The combined search yielded 94 publications, of which 56 were irrelevant, 2 were excluded because they were conducted on overlapping populations with other studies, 6 were commentaries, reviews, or meta-analyses, and 4 did not report the relevant genotype frequencies. As a result, 20 articles comprising 3,300 cases and 3,550 controls were included for the CYP1A1*2A polymorphism (Table 1) . Seventeen articles fulfilled the criteria to be considered epidemiologic studies. The genotype distribution in controls was not in Hardy-Weinberg equilibrium in 1 article (21) , and this information was not provided in 3 articles (22) (23) (24) . Regarding the CYP1A1*2C polymorphism, there were 12 articles with 1,685 cases and 2,253 controls (Table 2) . Eleven articles met the criteria to be considered epidemiologic studies. Controls in 1 article were not in Hardy-Weinberg equilibrium (25) . The characteristics of the included articles are summarized in Table 3 . Summaries of the CYP1A1*2A and CYP1A1*2C polymorphisms and leukemia risk are shown in Tables 4-6.
Genome-wide association studies
We identified 14 genome-wide association studies that searched for genetic variants for leukemia. None of these studies reported significant associations with CYP1A1 polymorphisms. The authors did not report whether CYP1A1 polymorphisms were examined, but all provided the types and manufacturers of the microarray chips used in the studies. To determine whether the single nucleotide polymorphisms examined in these studies could provide information relevant to . None of the chips used in these studies included CYP1A1 polymorphisms. Our search for genome-wide association studies that presented information on the association of CYP1A1 polymorphisms with the risks of all cancers was also negative. Similarly, we found that CYP1A1 polymorphisms were not included in the platforms commonly used in genome-wide association studies, which was consistent with the findings of other studies (9, 26, 27) .
When all leukemia was considered, the pooled estimates showed an increased risk under the heterozygous model (odds ratio (OR) = 1.22, 95% confidence interval (CI): 1.02, 1.47). Studies of Caucasians and those of Asians were eligible for pooled analyses by ethnicity. Significant associations were shown in studies of Caucasians (for TC vs. TT, OR = 1.46, 95% CI: 1.13, 1.88; for CC/TC vs. TT, OR = 1.36, 95% CI: 1.09, 1.69), whereas no association was suggested in studies of Asians. By leukemia subtype, subgroup analyses were possible for studies of acute lymphoid leukemia and for those of acute myeloid leukemia. Increased risks were shown in studies of both acute lymphoid leukemia (for CC/TC vs. TT, OR = 1.28, 95% CI: 1.03, 1.59) and acute myeloid leukemia (for CC vs. TT, OR = 1.91, 95% CI: 1.04, 3.50; for CC/TC vs. TT, OR = 1.50, 95% CI: 1.06, 2.10). There was an increased risk shown in studies of childhood leukemia (for CC/TC vs. TT, OR = 1.24, 95% CI: 1.02, 1.51) and in studies of adult cases (for TC vs. TT, OR = 1.55, 95% CI: 1.18, 2.02).
Further stratification by a combination of leukemia subtype, subject's age, and ethnic group was possible for studies of acute lymphoid leukemia in Caucasians, childhood acute lymphoid leukemia in Caucasians, childhood leukemia in Caucasians, childhood acute lymphoid leukemia in all ethnicities, and acute lymphoid leukemia in Asians. Among all acute lymphoid leukemia cases in Caucasians, 95.3% were children who accounted for 90.6% of childhood leukemia cases in Caucasians. Increased risks were shown among childhood acute lymphoid leukemia in Caucasians Among all the covariates investigated by meta-regression analyses, ethnicity was a factor that contributed to the observed heterogeneity across all studies under the heterozygous model (P = 0.029) and the dominant model (P = 0.025). Similar results were also found for studies of acute lymphoid leukemia (for CT vs TT, P = 0.010; for CC/CT vs. TT, P = 0.009). Logistic regression analyses did not show that the odds ratios of leukemia risk and CYP1A1*2A were different for Caucasians and Asians or for acute lymphoid leukemia and acute myeloid leukemia (data not shown).
Interactions between CYP1A1*2A and GSTM1 genotypes Four of 9 studies included 659 cases of childhood acute lymphoid leukemia and assessed the interactions between CYP1A1*2A and GSTM1 genotypes. The GSTM1 null genotype was found to increase the acute lymphoid leukemia risk for child carriers of the CYP1A1*2A variant alleles (OR = 1.89, 95% CI: 1.30, 2.74) without between-study heterogeneity (I 2 = 0.0%) (Figure 2 ). In contrast, the GSTM1 genotype was not associated with an increased risk (OR = 1.21, 95% CI: 0.85, 1.73) with moderate heterogeneity (I 2 = 44.4%). Logistic regression analyses did not show a significant interaction between the CYP1A1*2A variant alleles and the GSTM1 null genotype (OR = 0.71, 95% CI: 0.43, 1.17; P = 0.181). Sensitivity analyses did not identify any single study that markedly influenced the pooled estimates (data not shown).
CYP1A1*2C polymorphism
When all leukemia was considered, associations of increased risks were shown (for GA vs. AA, OR = 
Meta-Analysis of CYP1A1 Polymorphisms and Leukemia Risk 499
Am J Epidemiol. 2013;178(4):493-507 Because of the low number of homozygous (GG) individuals in cases and controls, pooled analyses under the homozygous and recessive models were not conducted in subgroup analyses. Studies of leukemia in Caucasians were eligible for pooling estimates by ethnicity, and increased risks were shown (for GA vs. AA, OR = 1.78, 95% CI: 1.37, 2.33; for GG/GA vs. AA, OR = 1.75, 95% CI: 1.08, 2.83) (Figure 3 ). The increased risks were largely due to the effect of adult cases. By leukemia subtype, subgroup analyses were eligible for studies of acute lymphoid leukemia, and the results showed no association. By age, pooled estimates for studies of all childhood leukemia did not suggest significant associations. In contrast, there was an increased risk in studies of all adult leukemia (for GA vs. AA, OR = 2.06, 95% CI: 1.46, 2.90; for GG/GA vs. AA, OR = 2.09, 95% CI: 1.52, 2.90). Further stratification by a combination of leukemia subtype, age, and ethnicity was possible only for studies of childhood acute lymphoid leukemia. Eighty-three percent of acute lymphoid leukemia cases were children. Subgroup analyses by childhood acute lymphoid leukemia generated similar results as for the meta-analysis of the acute lymphoid leukemia subgroup of all ages (data not shown). Low to moderate heterogeneity was observed under the heterozygous and dominant models in the subgroup analyses by acute lymphoid leukemia and by childhood leukemia (I 2 range, 23.8%-42.8%). There was high heterogeneity under the heterozygous and dominant models in the overall analysis, in the subgroup analyses by Caucasian ethnicity, and in the subgroup analyses by adult leukemia (I 2 range, 51.7%-67.8%). The sensitivity analyses identified a nonepidemiologic study (28) as an outlier, and the high heterogeneity was substantially reduced after removing this study (I 2 range, 0.0%-34.6%). For all the meta-analyses, the odds ratios were not changed significantly when tested by either leave-1-out sensitivity analyses or when only high-quality studies were included. A strong correlation between the magnitude of log odds ratios and age was identified under the dominant model (P = 0.016). Logistic regression analyses showed that the odds ratios for leukemia risk and CYP1A1*2C were different for children and adults (for GA vs. AA, OR = 0.49, 95% CI: 0.37, 0.66; P < 0.001; for GG/AG vs. AA, OR = 0.51, 95% CI = 0.38, 0.68; P < 0.001).
Assessment of publication bias
For both CYP1A1*2A and CYP1A1*2C polymorphisms, asymmetry in the funnel plots was not observed under any comparisons, and significant asymmetry was not suggested by Egger's linear regression test or Begg's rank correlation test (data not shown).
Cumulative epidemiologic evidence
The Venice criteria were applied to all significant associations (P < 0.05) identified by the meta-analyses to evaluate the epidemiologic credibility of each (Tables 4-6, Web Appendix 1 available at http://aje.oxfordjournals.org/).
For the CYP1A1*2A polymorphism, there were 10 significant associations. The amount of evidence was graded "A" for 3 associations and "B" for 7 associations. Replication was graded "A" for 5 associations, "B" for 1 association, and "C" for 4 associations. Protection from bias was graded "B" for 8 associations and "C" for 2 associations. Six associations (CT c The number of subjects who were homozygous for the rare allele (CC) or the number of subjects who were both homozygous (CC) and heterozygous (CT).
d P value for the summary effect of the Z test. e A score of "A" indicates strong epidemiologic credibility, "B" indicates moderate epidemiologic credibility, and "C" indicates weak epidemiologic credibility. A score of "A" in all 3 categories indicates a large amount of evidence with extensive replication and protection from bias. Therefore, the cumulative epidemiologic evidence of statistically significant associations was considered to be strong if all 3 grades were "A," moderate if all 3 grades were either "A" or "B," and weak if any grades were "C."
f When meta-analyses were restricted to high-quality studies, the odds ratios were significantly different and the heterogeneity remained (for CC/TT, OR = 1.98, 95% CI: 0.97, 4.03, P = 0.061; I 2 = 58.8%, P = 0.046; for CC+CT/TT, OR = 1.45, 95% CI: 0.92, 2.29, P = 0.108; I 2 = 75.5%, P = 0.003).
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Am J Epidemiol. 2013;178(4):493-507 vs. TT and CC/CT vs. TT in all leukemia in Caucasians; CT vs. TT and CC/CT vs. TT in childhood acute lymphoid leukemia in Caucasians; CC/CT vs. TT in all childhood leukemia; and CT vs. TT in all adult leukemia) received either an "A" or "B" grade in all 3 criteria and were thus scored as having moderate evidence. The remaining associations received a "C" grade in 1 or more criteria and were scored as having weak cumulative evidence. The association of childhood leukemia with the combined effect of GSTM1 null and CYP1A1*2A polymorphisms was graded "B, A, B" (moderate evidence). Abbreviations: CI, confidence interval; CYP1A1, cytochrome P450, family 1, subfamily 1A1 gene; OR, odds ratio. * The P value of the Cochrane Q test of between-study heterogeneity was <0.10. a I 2 value for between-study heterogeneity. b Number of studies included in the meta-analysis. c The number of subjects who were homozygous for the rare allele (GG) or the number of subjects who were both homozygous (GG) and heterozygous (GA).
d P value for the summary effect of the Z test. e A score of "A" indicates strong epidemiologic credibility, "B" indicates moderate epidemiologic credibility, and "C" indicates weak epidemiologic credibility. A score of "A" in all 3 categories indicates a large amount of evidence with extensive replication and protection from bias. Therefore, the cumulative epidemiologic evidence of statistically significant associations was considered to be strong if all 3 grades were "A," moderate if all 3 grades were either "A" or "B," and weak if any grades were "C." (28) on adult acute myeloid leukemia in Caucasians was identified as an outlier by the sensitivity analyses. The between-study heterogeneity was substantially reduced after removing this study (range of Q statistic P values, 0.105-0.992; range of I 2 values, 0.0%-34.6%), and the corresponding odds ratios were not significantly changed.
g Pooled analyses were not conducted because of a small number of homozygous (GG) carriers in cases and controls. (28) on adult acute myeloid leukemia in Caucasians. It was a nonepidemiologic study and was identified as an outlier by the sensitivity analyses.
c Number of studies included in the meta-analysis. d The number of subjects who were homozygous for the rare allele (GG) or the number of subjects who were both homozygous (GG) and heterozygous (GA).
e P value for the summary effect of the Z test. f A score of "A" indicates strong epidemiologic credibility, "B" indicates moderate epidemiologic credibility, and "C" indicates weak epidemiologic credibility. A score of "A" in all 3 categories indicates a large amount of evidence with extensive replication and protection from bias. Therefore, the cumulative epidemiologic evidence of statistically significant associations was considered to be strong if all 3 grades were "A," moderate if all 3 grades were either "A" or "B," and weak if any grades were "C." For the CYP1A1*2C polymorphism, there were 8 significant associations. The amount of evidence was graded "A" for 1 association and "B" for 7 associations. Replication was graded "B" for 2 associations and "C" for 6 associations. Protection from bias was graded "B" for all 8 of the associations. As a result, 2 associations in all leukemia combined (GG vs. AA and GG/GA vs. AA) received a "B" grade in all 3 criteria and were thus scored as having moderate evidence. The remaining associations received a "C" grade in 1 or more criteria and were scored as having weak cumulative evidence. It should be noted that, after excluding a lowquality study (28) , the heterogeneity was substantially reduced in 4 associations (GA vs. AA and GG/GA vs. AA in all leukemia combined and GA vs. AA and GG/GA vs. AA in all adult leukemia), whereas the significance remained. These resulted in a shift from a "C" to either an "A" or "B" grade for replication in all 4 of the associations. Thus, the cumulative evidence of the 4 associations was reconsidered to be moderate (Table 6 ).
The associations between CYP1A1 polymorphisms and leukemia risks were also stratified by type of case (incident or prevalent), and the epidemiologic credibility was evaluated (Web Appendix 2).
DISCUSSION
Our meta-analysis showed that the strength of cumulative evidence was moderate for the associations of the CYP1A1*2A and CYP1A1*2C polymorphisms with leukemia risks. For the CYP1A1*2A polymorphism, the cumulative evidence was considered moderate for the associations with 1) all leukemia or acute lymphoid leukemia among Caucasians; 2) all leukemia or acute lymphoid leukemia among children; 3) all leukemia among adults; and 4) all leukemia or acute lymphoid leukemia among Caucasian children. Because most Caucasian cases were childhood acute lymphoid leukemia, the observed associations in all Caucasian subgroups might be the effect of childhood acute lymphoid leukemia in Caucasians. Regarding the other groups, significant associations were shown in only 1 of the 4 genetic models, and the associations were considered less credible (29) . When gene-gene interactions were investigated, the risk of developing acute lymphoid leukemia was further increased for child carriers of both the CYP1A1*2A variant and the GSTM1 null genotype. Although the gene-gene interactions were not statistically established, the power of the test was low. Therefore, a possible role of the gene-gene interactions in leukemogenesis cannot be ruled out. Caucasians were shown to be more susceptible to acute leukemia than were Asians (3, 30) . Our meta-analysis indicated that, unlike in Caucasians, in Asians who carry the CYP1A1*2A variant alleles, there is no increased leukemia risk. Considering the presence of heterogeneity between Asian studies, we hypothesized that the CYP1A1*2A polymorphism may contribute to an increased risk of leukemia by interacting with other genetic factors in Asians. Subsequent studies evaluating potential single nucleotide polymorphism-single nucleotide polymorphism interactions between CYP1A1 and other genes among different ethnic groups may elucidate this issue.
The CYP1A1 polymorphisms have been reported to alter the susceptibility to many cancers, including lung (31) and colorectal (32) cancers. Individuals who have a genetic deficiency in the detoxifying enzyme, such as the GSTM1 null genotype, have been found to have increased risk of developing lung and bladder cancers (33) . When gene-gene interactions were considered, the increase in cancer risk was more significant, which could be due to persistence of CYP1A1 inducers (34) . For the CYP1A1*2A polymorphism, these observations are consistent with our meta-analysis, which demonstrated an increased risk of childhood acute lymphoid leukemia and a potential joint effect with the GSTM1 null genotype. Taken together, these findings support the hypothesis that higher activity of the phase I oxidative pathway is linked to enhanced carcinogenesis (35) .
The CYP1A1*2C polymorphism has been shown to be associated with an early onset of breast and colorectal cancers (36, 37) . In addition, children are more susceptible than adults to a variety of environmental toxicants because of several factors, such as higher rates of cell proliferation and physiological immaturity (38) . Therefore, the effect of metabolic gene polymorphisms would be more evident in children. However, our meta-analysis showed that the CYP1A1*2C polymorphism is associated with an increased leukemia risk in adults (moderate cumulative evidence) but not in children (weak cumulative evidence). Studies examining the effects of CYP1A1*2C mutations on enzyme activity in various models have produced conflicting results (39); thus, our results are not explainable on the basis of the present information. Here we proposed 2 hypotheses regarding the role of the CYP1A1*2C polymorphism in leukemogenesis. One hypothesis is that the enzymatic activity of CYP1A1*2C mutant protein is elevated only in the context of adult xenobiotic metabolizing systems. On the other hand, in this meta-analysis, 89.9% of childhood leukemia was acute lymphoid leukemia and 82.3% of adult leukemia was myeloid leukemia. Therefore, the different associations between adults and children might be attributable to the leukemia subtypes. Compared with acute lymphoid leukemia, there are more xenobiotic agents, including benzene, tobacco smoke, and pharmaceuticals (for example, busulfan, chlorambucil, cyclophosphamide, etoposide, and melphalan) that have been found to increase susceptibility to myeloid leukemia (4). Thus, the effects of the CYP1A1*2C polymorphism would be more pronounced for myeloid leukemia than for acute lymphoid leukemia.
Our study has several limitations. First, classification of leukemia in the eligible studies varied, by using both the French, American, and British system of immunophenotyping (40) and the World Health Organization's system (41) . The differences between the classification systems could lead to mixing of tumor types, resulting in inaccurate pooled estimates and sources of heterogeneity. Second, the subgroup meta-analyses considering gene-gene interactions between the CYP1A1*2A and GSTM1 genotypes did not include all of the studies because a small number of authors could not share their original data, so selection bias may have occurred. Furthermore, the small sample size in the subgroup analyses limited the precision of the pooled estimates. Third, because only published studies were included in the meta-analysis, publication bias may have occurred, even though the use of a statistical test did not show it. Fourth, the design of some included studies may be problematic in ways that are impossible to ascertain by using the published information because genetic association studies sometimes lack important details (42) . Fifth, the "Caucasian" and "Asian" designations may comprise individuals of various races and ethnicities, and hidden population stratification cannot be completely ruled out. Finally, the quality of the individual studies included in our meta-analysis was assessed to minimize potential bias and genotyping errors. It is known that a validated quality assessment system does not currently exist (43, 44) , and it is evident that the cutoff between high and low quality in our system is somewhat subjective. Despite these limitations, the application of our quality assessment system on the CYP1A1*2C polymorphism showed an apparent reduction in heterogeneity when the analyses were restricted to high-quality studies. If high-quality studies are more likely to yield valid information than are studies overall, we can confirm that the CYP1A1*2C polymorphism played a role in leukemogenesis.
After extensive research on this issue, we demonstrated through our meta-analysis that genetic variations within CYP1A1 play a role in leukemogenesis. In addition, we provided evidence that the CYP1A1 polymorphisms could have different effects in leukemogenesis between subtypes of leukemia and between adult and childhood leukemia. These new insights warrant further research into the molecular mechanisms underlying the role of CYP1A1 polymorphisms in leukemogenesis.
